Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative intraperitoneal chemotherapy with HIPEC plus perioperative FLOT4 in advanced gastric cancer
2020-001419-25Phase 3Active
- Sponsor
- Jagiellonian University Medical College
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of irinotecan in gastric adenocarcinoma (2 arms), sponsored by Jagiellonian University Medical College. Primary endpoint: Peritoneal recurrence rate at 6 months after gastrectomy. Started Jan 2021; status: active.
02
Drugs
irinotecan
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on 2020-001419-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001419-25.